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Serum IgG2 levels are specifically 
associated with whole-body insulin-
mediated glucose disposal in non-
diabetic offspring of type 2 diabetic 
individuals: a cross-sectional study
Teresa Vanessa Fiorentino1, Elena Succurro1, Franco Arturi1, Aida Giancotti2, 
Cinzia Peronace2, Angela Quirino2, Franz Sesti3, Francesco Andreozzi1,  
Marta Letizia Hribal  1, Francesco Perticone1, Alfredo Foc2 & Giorgio Sesti1
Preclinical studies suggested that IgG2c isotype may specifically impair skeletal muscle insulin 
sensitivity in mice. In this study we investigated the association between serum levels of the four IgG 
subclasses and insulin sensitivity in non-diabetic individuals. Total IgG, IgG1, IgG2, IgG3 and IgG4 
levels were measured in 262 subjects. Whole-body insulin sensitivity was assessed by euglycemic 
hyperinsulinemic clamp. IgG2 levels were positively correlated with BMI, waist circumference, 2-h post-
load glucose levels and complement C3. Serum IgG2, but not IgG1, IgG3 and IgG4 levels were negatively 
correlated with whole-body insulin sensitivity (r = −0.17; P = 0.003) and muscle insulin sensitivity index 
(r = −0.16; P = 0.03) after adjustment for age and gender. No significant correlation was found between 
IgG2 levels and hepatic insulin resistance assessed by HOMA-IR and liver IR index. In a multivariable 
regression analysis including variables known to affect insulin sensitivity such as age, gender, BMI, 
smoking, lipids, inflammatory markers, fasting and 2-h post-load glucose levels, IgG2 levels were 
independently associated with insulin-stimulated glucose disposal (β = −0.115, 95% CI: −0.541 to 
−0.024; P = 0.03). These data demonstrate the independent association between higher levels of IgG2 
and decreased whole-body insulin sensitivity, thus confirming in humans the animal-based evidence 
indicating the pathogenic role of IgG2 in insulin resistance.
Observational studies have solidified the concept that low-grade inflammation plays a pathophysiological role 
in insulin resistance associated with type 2 diabetes mellitus1–7. Markers of inflammation have been extensively 
studied in these metabolic conditions, with convincing evidence showing that elevated concentrations of C reac-
tive protein, fibrinogen, complement C3, and white blood cells count are predictors of type 2 diabetes. In addi-
tion to these reliable markers of inflammation, widely used in clinical practice, also immunoglobulin G (IgG) 
level, an indicator of adaptive immune system activation, has been associated with obesity and type 2 diabetes in 
cross-sectional and prospective studies8–10. Experimental studies in mice have suggested a role of B cells in the 
pathogenesis of insulin resistance associated with diet-induced obesity11,12. In particular, it has been shown that 
transfer of proinflammatory IgG2c isotype purified from sera of diet-induced obese mice caused insulin resist-
ance and glucose intolerance in the recipient rodents11. More recently, it has been reported that IgG2c isotype, 
but not IgG1 or IgG2b, selectively caused skeletal muscle insulin resistance in diet-induced obese mice by acti-
vating the IgG receptor FcγRIIB in endothelium12. The activation of FcγRIIB by IgG2c isotype from diet-induced 
obese mice, in turn, impaired endothelial cell insulin transcytosis, resulting in reduced insulin delivery to skeletal 
muscle and impairment in muscle glucose disposal12. Furthermore, IgG isolated from individuals with type 2 
diabetes caused glucose intolerance and insulin resistance in IgG-deficient mice via FcγRIIB, indicating that 
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similar processes may be effective in humans12. Prompted by the need to better understand the pathophysiolog-
ical role of human IgG isotypes in glucose homeostasis disorders, we sought to determine their potential role in 
insulin resistance. To address this issue, we assessed human serum IgG isotypes (IgG1, IgG2, IgG3, and IgG4) in 
non-diabetic offspring of type 2 diabetic individuals and correlated their concentration with insulin sensitivity 
assessed using the euglycemic hyperinsulinemic clamp.
Results
Clinical features and biochemical findings of the study group stratified by gender are shown in Table 1. 
Men were more likely to be current smokers and exhibited a worse cardio-metabolic risk profile includ-
ing higher waist circumference values, blood pressure, triglycerides and fasting plasma glucose levels, and 
lower HDL cholesterol, muscle insulin sensitivity index and insulin-stimulated glucose disposal, assessed by 
euglycemic-hyperinsulinemic clamp. No gender-specific differences were observed in the other indexes of insu-
lin sensitivity either based on fasting measurements such as QUICKI, and homeostasis model assessment insu-
lin resistance (HOMA-IR) or derived by OGTT including liver insulin resistance (liver IR) index, glucose0–30 
(AUC) × insulin0–30 (AUC) index, Stumvoll Insulin Sensitivity Index (ISI), Gutt’s ISI0,120, and Matsuda index. 
Additionally, no gender-specific differences were observed in total IgG or IgG isotypes levels except for IgG4, 
which were higher in men (Table 1).
Univariate correlations between circulating IgG isotypes levels and anthropometric and metabolic variables 
are shown in Table 2. After adjusting for age and gender, only IgG2 levels exhibited a significant correlation with 
anthropometric and metabolic traits with the exception of IgG1, which displayed an inverse relationship with 
percentage of fat free mass. Particularly, IgG2 levels were positively correlated with BMI, waist circumference, 
2-h post-load glucose levels and complement C3. Serum IgG2, but not IgG1, IgG3, and IgG4 levels were nega-
tively correlated with insulin-stimulated glucose disposal, and with the OGTT-derived insulin sensitivity indexes 
Stumvoll ISI, Matsuda, Gutt’s ISI0,120, and muscle insulin sensitivity index (Table 2). No significant association 
between IgG2 concentrations and hepatic insulin sensitivity estimated by HOMA-IR, liver IR and glucose0–30 
(AUC) × insulin0–30 (AUC) index was observed. The correlation between IgG2 levels and insulin-stimulated 
glucose disposal remained significant after further adjusting for BMI in addition to gender and age (P = 0.005). 
By contrast, the correlations between IgG2 levels and 2-h post-load glucose or complement C3 levels were no 
longer statistically significant after adjustment for BMI. Furthermore, the negative relationship between IgG2 
levels and insulin-stimulated glucose disposal was statistically significant in the subgroup of subjects with normal 
glucose tolerance (n = 200) as well as in the small subgroup of individuals with impaired glucose tolerance and/
or impaired fasting glucose (n = 62) (Suppl. Tables 1 and 2).
In order to confirm the specific association between insulin-stimulated glucose disposal and IgG2 levels we 
subdivided the whole study population in tertiles of insulin-stimulated glucose disposal. After adjusting for age 
and gender serum IgG2 levels, but not IgG1, IgG3, and IgG4 levels progressively decreased in the intermediate 
and highest tertiles of insulin-stimulated glucose disposal in comparison to the lowest tertile (Table 3).
Next, we built three models of multivariable regression analysis including variables known to affect insu-
lin sensitivity to evaluate the independent contribution of IgG2 levels to insulin-stimulated glucose disposal 
(Table 4). Comparison of standardized coefficients allowed the determination of the relative strength of each 
trait association with insulin-stimulated glucose disposal. We found that IgG2 levels were associated with 
insulin-stimulated glucose disposal independently of age, gender, and BMI (Table 4, model 1). The associa-
tion between IgG2 levels and insulin-stimulated glucose disposal remained significant when smoking status, 
blood pressure, total and HDL cholesterol, triglycerides, fasting and 2-h post-load glucose concentrations were 
included in the model in addition to age, gender, and BMI (Table 4, model 2). Similar results were obtained when 
waist circumference replaced BMI in the regression model (Table 4, model 3). In a full adjusted model including 
hsCRP, white blood cells count, and complement C3 in addition to variables analyzed in the model 2, IgG2 levels 
were independently associated with insulin-stimulated glucose disposal (β = −0.115, P = 0.03), with the model 
explaining 32.9% of variation (R2 = 0.324) of insulin-stimulated glucose disposal.
Discussion
Prior cross-sectional and prospective studies have shown that total serum IgG levels, a nonspecific marker 
of the adaptive immune system activation, are associated with obesity and type 2 diabetes8–10. Additionally, 
animal-based studies have suggested that IgG2c isotype, but not IgG1 or IgG2b, may have a role in causing a selec-
tive state of muscle insulin resistance in diet-induced obese mice11,12. These observations provided the rationale to 
investigate the relationship between serum IgG1, IgG2, IgG3, and IgG4 isotypes and insulin sensitivity in humans. 
In this cross-sectional study including nondiabetic offspring of type 2 diabetic individuals with a wide range 
of BMI, we found that in univariate analysis serum concentrations of IgG2, but not IgG1, IgG3, or IgG4, were 
inversely associated with whole-body insulin-stimulated glucose disposal. This association remained statistically 
significant in multivariate analysis after adjustments for potential confounders such as indexes of adiposity, lipids 
levels, measures of glucose tolerance status, and markers of inflammation. Keeping in mind that under the hyper-
insulinemic conditions reached during euglycemic hyperinsulinemic clamp studies (with insulin infusion rate 
fixed 40 mU/m2 per min) hepatic glucose production is suppressed and 80–90% of the infused glucose is taken 
up by skeletal muscle, insulin-stimulated glucose disposal may be assumed to primarily reflect skeletal muscle 
insulin sensitivity13. Notably we found that IgG2 levels were negatively correlated with both insulin-stimulated 
glucose disposal and muscle insulin sensitivity index. Accordingly, IgG2 levels were negatively correlated with 
surrogate OGTT-derived indexes including Stumvoll ISI, Gutt’s ISI0,120, Matsuda which are strongly correlated 
with skeletal muscle insulin sensitivity14. By contrast, no significant correlations were found between IgG2 levels 
and HOMA-IR index, a surrogate index of liver insulin resistance, primarily reflecting hepatic glucose produc-
tion14, and the liver IR index and glucose0–30 (AUC) × insulin0–30 (AUC) index, which were specifically developed 
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to estimate hepatic insulin resistance14,15. These results are in line with animal-based evidence showing that IgG2c 
affects muscle rather than hepatic insulin sensitivity12. To the best of our knowledge, this is the first study in 
humans assessing the relationship between serum IgG isotypes levels and whole-body insulin sensitivity eval-
uated using the euglycemic hyperinsulinemic clamp. Preclinical studies have shown that visceral adipose tissue 
lysates from mice fed with high-fat diet displayed higher concentrations of IgG2c, which are responsible for selec-
tive muscle insulin resistance11,12, and therefore, it is conceivable that increased adipose tissue mass may explain 
the relationship between IgG2 and insulin sensitivity. We found that the association between IgG2 levels and 
whole-body insulin sensitivity remained statistically significant after adjustment for measures of adiposity such as 
BMI, and waist circumference, it is thus, unlikely that an expansion of fat mass may fully explain this association.
Alternatively, the association between IgG2 and insulin sensitivity may reflect a generalized subclinical 
inflammatory state rather than a specific effect of IgG2 isotype on insulin sensitivity. However, we found that the 
association between IgG2 levels and insulin-stimulated glucose disposal remained statistically significant after 
adjustment for subclinical inflammatory markers such as hsCRP, complement C3 and white blood cell count; 
this result arguing against the possibility that a dysregulation in the production of inflammatory molecules may 
Variables Overall cohort Men Women P value
Number 262 137 125 —
Age (yrs) 39 ± 9 40 ± 10 38 ± 9 0.43
BMI (kg/m2) 30.0 ± 6.2 30.0 ± 5.0 30.1 ± 7.3 0.85
Normal weight/overweight/obese (n) 56/83/123 20/51/66 36/32/57 0.01
Waist circumference (cm) 99 ± 14 101 ± 12 96 ± 14 0.002
Fat body mass (%) 31 ± 9 27 ± 7 36 ± 8 <0.0001
Fat free mass (%) 69 ± 9 73 ± 7 64 ± 8 <0.0001
Systolic blood pressure (mmHg) 127 ± 15 131 ± 12 124 ± 17 <0.0001
Diastolic blood pressure (mmHg) 81 ± 11 84 ± 10 78 ± 11 <0.0001
Total Cholesterol (mg/dl) 195 ± 39 197 ± 37 192 ± 40 0.23
HDL Cholesterol (mg/dl) 50 ± 14 44 ± 11 56 ± 13 <0.0001
Triglycerides (mg/dl) 119 ± 69 137 ± 75 99 ± 55 <0.0001
Fasting Glucose (mg/dl) 90 ± 9 92 ± 9 88 ± 9 0.01
2-h glucose (mg/dl) 114 ± 26 113 ± 24 115 ± 27 0.44
Fasting insulin (µU/ml) 13.7 ± 8.8 14.4 ± 9.4 12.9 ± 8.0 0.19
HbA1c (%) [mmol/mol] 5.4 ± 0.3[36 mmol/mol]
5.4 ± 0.3
[36 mmol/mol]
5.4 ± 0.3
[36 mmol/mol] 0.31
Total IgG (mg/ml) 11.4 ± 2.6 11.2 ± 2.6 11.7 ± 2.6 0.09
IgG1 (mg/ml) 6.5 ± 1.7 6.4 ± 1.9 6.6 ± 1.6 0.40
IgG2 (mg/ml) 4.0 ± 1.5 3.9 ± 1.3 4.1 ± 1.7 0.15
IgG3 (mg/ml) 0.40 ± 0.20 0.38 ± 0.17 0.42 ± 0.22 0.09
IgG4 (mg/ml) 0.65 ± 0.58 0.75 ± 0.17 0.42 ± 0.22 0.003
hsCRP (mg/l) 3.1 ± 4.2 2.9 ± 4.7 3.4 ± 3.6 0.22
Complement C3 (g/l) 1.19 ± 0.26 1.19 ± 0.23 1.18 ± 0.29 0.70
White blood cell count (cell/mm3) 7068 ± 1966 7205 ± 2033 6919 ± 1887 0.24
Insulin-stimulated glucose disposal (mg * min−1 * kg FFM −1) 7.1 ± 3.7 6.4 ± 3.2 7.8 ± 4.1 0.004
HOMA-IR 3.0 ± 2.0 3.2 ± 2.1 2.8 ± 1.8 0.07
Liver IR index 2.97 ± 0.40 2.99 ± 0.41 2.96 ± 0.39 0.59
QUICKI 0.25 ± 0.04 0.25 ± 0.04 0.26 ± 0.04 0.10
Glucose0–30 (AUC) × insulin0–30 (AUC) 35.0 ± 23.7 36.7 ± 22.3 33.1 ± 25.2 0.07
Stumvoll ISIOGTT 0.061 ± 0.058 0.059 ± 0.068 0.063 ± 0.048 0.21
Matsuda index 74 ± 48 71 ± 49 78 ± 46 0.14
Gutt’s ISI0,120 19.2 ± 7.1 19.3 ± 7.4 19.1 ± 6.7 0.86
Muscle insulin sensitivity index 1.19 ± 1.12 1.05 ± 0.99 1.29 ± 1.21 0.03
NGT/IFG/IGT/combo IFG + IGT (n) 200/21/30/11 100/17/12/8 100/4/18/3 0.01
Smoking status (never smokers/current smokers/ex-smokers) 164/66/32 74/41/22 90/35/10 0.009
Table 1. Clinical characteristics of the study group. Data are means ± SD. Triglycerides, fasting insulin, 
HOMA-IR index, glucose0–30 (AUC) × insulin0–30 (AUC), Matsuda, Gutt’s ISI0,120, Stumvoll ISIOGTT, Muscle 
insulin sensitivity index, and hsCRP levels were log transformed for statistical analysis, but values in the 
table represent a back transformation to the original scale. Differences between means were compared 
using unpaired Student’s t test. Categorical variables were compared by χ2 test. NGT = normal glucose 
tolerance; IGT = impaired glucose tolerance; IFG = impaired fasting glucose; BMI = body mass index; 
hsCRP = high sensitivity C reactive protein; HbA1c = glycated hemoglobin; HDL = high density lipoprotein; 
HOMA-IR = homeostasis model assessment insulin resistance; Liver IR index = liver insulin resistance index.
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explain the relationship between IgG2 and insulin sensitivity. The view that IgG2 is a bona fide modulator of insu-
lin sensitivity is also supported by the finding that IgG1, IgG3, and IgG4 are not associated with insulin-stimulated 
glucose disposal. Moreover previous studies have reported that insulin resistance in obese subjects is associated 
with a distinct profile of IgG11, and that IgG2c and their sialylation levels play a causal role in obesity-induced 
insulin resistance in mice by modulating insulin endothelial transcytosis via FcγRIIB receptor12.
Our study has some strengths including the demographically homogeneous cohort of offspring of patients 
with type 2 diabetes, equally comprising both male and female subjects, the wealth of exhaustive anthropometric 
and metabolic variables collected by a trained staff according to an international standardized protocol, the use 
of the gold standard hyperinsulinemic euglycemic clamp for insulin sensitivity assessment, and the exclusion of 
confounding conditions potentially affecting both insulin sensitivity and immune response.
Notwithstanding, the current study has a number of potential limitations that should be recognized. First, 
the present study has a cross-sectional design, and thus it does not allow us to definitely establish the causal rela-
tionship between IgG2 levels and muscle insulin sensitivity or to draw any conclusion on the role of IgG2 in the 
occurrence of insulin resistance characterizing type 2 diabetes, even though prior preclinical evidence supports 
the biological plausibility of the present findings. Second, the present results might have been influenced by the 
presence of a family history of type 2 diabetes. Indeed, it has been reported that parental diabetes is associated 
with a significant increase in total IgG in the offspring10. Relatives share not only genetic determinants influenc-
ing the immune response but also environmental factors such as exposure to infections. Therefore, the extension 
of the present results to the general population must be made with caution. Third, the present results are only 
based on White individuals, and generalizing them to other ethnic groups may be inappropriate, because differ-
ences between ethnic groups in concentrations of IgG, IgA, and IgM have been reported16. Moreover, we did not 
have access to direct, detailed measures of hepatic insulin resistance by clamp combined with tracer technique 
since it is complex and expensive, and therefore not feasible for large epidemiological studies. However, we have 
employed validated proxy measures of hepatic insulin resistance including the liver IR index and glucose0–30 
(AUC) × insulin0–30 (AUC), which contain more information compared with fasting based measures utilized 
Total IgG (mg/ml) IgG1 (mg/ml) IgG2 (mg/ml) IgG3 (mg/ml) IgG4 (mg/ml)
Pearson’s 
correlation 
coefficient (r)
P 
value
Pearson’s 
correlation 
coefficient (r)
P 
value
Pearson’s 
correlation 
coefficient (r)
P 
value
Pearson’s 
correlation 
coefficient (r)
P 
value
Pearson’s 
correlation 
coefficient (r) P value
Age (yrs) −0.01 0.38* −0.07 0.26* 0.03 0.29* 0.01 0.95* −0.05 0.37*
BMI (kg/m2) 0.09 0.07 0.11 0.07 0.11 0.04 −0.04 0.48 0.03 0.58
Waist circumference (cm) 0.06 0.18 0.09 0.14 0.10 0.05 −0.05 0.36 0.01 0.81
Fat body mass (%) 0.08 0.09 0.12 0.057 0.04 0.28 −0.06 0.28 0.05 0.40
Fat free mass (%) −0.09 0.06 −0.12 0.04 −0.02 0.36 0.06 0.30 −0.03 0.63
Systolic blood pressure (mmHg) 0.04 0.25 0.01 0.82 0.03 0.31 0.01 0.81 0.03 0.58
Diastolic blood pressure (mmHg) 0.10 0.04 0.07 0.23 0.02 0.35 0.04 0.51 0.12 0.05
Total Cholesterol (mg/dl) −0.01 0.40 0.03 0.66 −0.01 0.43 0.04 0.52 0.03 0.64
HDL Cholesterol (mg/dl) −0.09 0.07 0.08 0.16 −0.09 0.08 −0.10 0.09 −0.06 0.32
Triglycerides (mg/dl) 0.05 0.21 0.08 0.18 0.07 0.12 0.12 0.06 0.06 0.28
Fasting Glucose (mg/dl) −0.01 0.48 −0.04 0.55 0.05 0.20 −0.08 0.18 −0.02 0.75
2-h glucose (mg/dl) 0.01 0.40 −0.03 0.62 0.14 0.01 −0.02 0.71 −0.05 0.36
HbA1c (%) [mmol/mol] −0.09 0.15 −0.04 0.68 0.03 0.38 0.04 0.61 0.05 0.57
hsCRP (mg/l) 0.05 0.20 0.02 0.75 0.10 0.06 −0.05 0.40 0.01 0.79
Complement C3 (g/l) 0.19 0.004 0.10 0.14 0.12 0.04 0.06 0.39 0.01 0.89
White blood cell count (cell/mm3) 0.01 0.47 0.01 0.84 0.06 0.16 0.01 0.83 0.02 0.73
Insulin-stimulated glucose 
disposal (mg * min−1 * kg FFM−1) −0.07 0.28 −0.02 0.76 −0.17 0.003 −0.04 0.44 −0.02 0.76
HOMA-IR 0.11 0.07 0.07 0.24 0.11 0.07 0.01 0.83 0.01 0.98
Liver IR index 0.10 0.11 0.11 0.09 0.09 0.14 0.09 0.08 −0.02 0.78
QUICKI index −0.06 0.17 −0.02 0.37 −0.09 0.07 0.03 0.29 0.01 0.44
Glucose0–30 (AUC) × insulin0–30 
(AUC) index 0.07 0.31 0.09 0.19 0.04 0.60 0.09 0.16 −0.04 0.47
Stumvoll ISIOGTT −0.09 0.18 −0.07 0.32 −0.19 0.007 0.003 0.96 −0.03 0.69
Matsuda index −0.10 0.07 −0.06 0.18 −0.14 0.02 −0.04 0.27 −0.01 0.48
Gutt’s ISI0,120 −0.09 0.09 −0.03 0.34 −0.17 0.006 −0.02 0.39 0.02 0.37
Muscle insulin sensitivity index −0.16 0.03 −0.06 0.39 −0.16 0.03 −0.13 0.09 0.04 0.58
Table 2. Age and gender adjusted univariate correlations between IgG isotypes levels and anthropometric 
and metabolic variables. *P values refer to results after analyses with adjustment for gender. Triglycerides, 
HOMA-IR index, glucose0–30 (AUC) × insulin0–30 (AUC), Stumvoll ISIOGTT, Matsuda, Gutt’s ISI0,120, Muscle 
insulin sensitivity index, and hsCRP levels were log transformed for statistical analysis. BMI = body mass index; 
HbA1c = glycated hemoglobin; hsCRP = high sensitivity C reactive protein; HDL = high density lipoprotein; 
HOMA-IR = homeostasis model assessment insulin resistance; Liver IR index = liver insulin resistance index.
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for the HOMA-IR index14,15. Finally, we cannot determine which potential underlying mechanism might induce 
an elevation in serum IgG2 in insulin resistant individuals. In this regard it should be noted that IgG2 isotype is 
strongly involved in the responses to bacterial capsular polysaccharide antigens17. Accordingly, previous stud-
ies have described increased circulating levels of IgG2 in individuals with periodontitis, predominantly reactive 
against the major oral pathogens, A. actinomycetemcomitans and P. gingivalis18–20. On the other hand several 
evidences have demonstrated the association between periodontal disease and the risk to develop type 2 diabetes 
supporting the idea that microbial-induced chronic activation of immune response may exert deleterious effects 
on glucose homeostasis21–23. Numerous studies have consistently pointed to a link between stimulation of toll-like 
receptors (TLRs), by binding of bacterial antigens, activation of pro-inflammatory signaling pathways and insu-
lin resistance24–26. Notably TLRs not only play a critical role in innate immunity but are also essential in the 
modulation of humoral responses27,28. In particular, TLR-4 activated by bacterial lipopolysaccharide (LPS) elicits 
IgG2 response by promoting Th1 associated cytokines production such as interleukin-12 (IL-12) and interferon 
gamma (IFN-γ)29,30. Importantly, alteration of gut microbiota or intestinal permeability, as observed in insulin 
resistance-related conditions, has been shown to increase gut-derived LPS circulating levels, thus resulting in 
systemic activation of TLR4-driven immune response25,31,32.
Considering these data we can hypothesize that all these mechanisms may be responsible for increased pro-
duction of IgG2, which, in turn, leads to insulin resistance, however we cannot exclude that the increased levels 
Tertile 1 Tertile 2 Tertile 3
P value adjusted 
for age and gender
Male/female 49/38 52/36 36/51 0.04
Age (yrs) 38 ± 10 40 ± 10 39 ± 9 0.47
BMI (kg/m2) 32.1 ± 6.4 30.4 ± 5.2 27.5 ± 6.1 <0.0001
Total IgG (mg/ml) 11.4 ± 2.5 11.4 ± 2.7 11.2 ± 2.5 0.87
IgG1 (mg/ml) 6.4 ± 1.6 6.5 ± 1.6 6.5 ± 1.8 0.79
IgG2 (mg/ml) 4.2 ± 1.5 4.0 ± 1.6 3.7 ± 1.3 0.04
IgG3 (mg/ml) 0.39 ± 0.21 0.41 ± 0.20 0.39 ± 0.18 0.75
IgG4 (mg/ml) 0.53 ± 0.06 0.69 ± 0.07 0.49 ± 0.05 0.42
Insulin-stimulated 
glucose disposal (mg * 
min−1 * kg FFM −1)
3.4 ± 0.9 6.5 ± 0.8 11.2 ± 3.0 <0.0001
Table 3. IgG isotypes levels of the study subjects stratified according to tertiles of insulin-stimulated glucose 
disposal. Data are means ± SD. Comparisons between the three groups were performed using a general linear 
model for multiple comparisons. BMI = body mass index.
Independent 
contributors
Standardized Coefficient β 
(95% CI) P
Model 1 includes IgG2, gender, age, 
and BMI.
BMI −0.353 (−0.278 to −0.145) <0.0001
Gender (male) −0.199 (−2.319 to −0.649) 0.001
IgG2 −0.141 (−0.622 to −0.071) 0.01
Model 2 includes IgG2, gender, 
age, BMI, smoking status, blood 
pressure, total and HDL cholesterol, 
triglycerides, fasting and 2 h post-
load plasma glucose.
2 h post-load glucose −0.240 (−0.052 to −0.020) <0.0001
BMI −0.220 (−0.193 to −0.055) <0.0001
Age 0.136 (0.001 to 0.094) 0.03
IgG2 −0.120 (−0.535 to −0.012) 0.02
Model 3 includes IgG2, gender, 
age, waist circumference, smoking 
status, blood pressure, total and HDL 
cholesterol, triglycerides, fasting and 
2 h post-load plasma glucose.
2 h post-load glucose −0.240 (−0.050 to −0.018) <0.0001
Waist circumference −0.201 (−0.084 to −0.023) 0.001
Age 0.146 (0.007 to 0.101) 0.03
IgG2 −0.130 (−0.563 to −0.038) 0.03
Model 4 IgG2, gender, age, BMI, 
smoking status, blood pressure, total 
and HDL cholesterol, triglycerides, 
fasting and 2 h post-load plasma 
glucose, hsCRP, white blood cell 
count, and complement C3.
2 h post-load glucose −0.217 (−0.047 to −0.015) <0.0001
BMI −0.153 (−0.169 to −0.014) 0.02
hsCRP −0.138 (−0.971 to −0.011) 0.04
IgG2 −0.115 (−0.541 to −0.024) 0.03
Table 4. Multiple regression analyses evaluating insulin-stimulated glucose disposal as dependent variable 
in four models of increasing complexity. Linear regression analysis in models including insulin-stimulated 
insulin sensitivity as dependent variables and gender, age, BMI, waist circumference, smoking status, systolic 
and diastolic blood pressure, total and HDL cholesterol, triglycerides, fasting and 2 h post-load plasma glucose, 
hsCRP, white blood cell count, and complement C3 as independent contributors. BMI = body mass index; 
hsCRP = high sensitivity C reactive protein; HDL = high density lipoprotein.
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of IgG2 found in subjects with a higher degree of insulin resistance represent an epiphenomenon of other altera-
tions, directly involved in the pathogenesis of insulin resistance.
In conclusion the present findings indicate that serum concentrations of IgG2, but not IgG1, IgG3 or IgG4, 
are associated with insulin-stimulated glucose disposal. The current study is novel because it suggests that the 
relationship between IgG2 isotype and insulin sensitivity is independent of important determinants of glucose 
metabolism including gender, age, adiposity, lipids, and subclinical inflammation. Future studies are needed to 
examine whether IgG2 plays a specific role in the development of type 2 diabetes independently of confounders 
factors.
Materials and Methods
The study sample comprised 262 non-diabetic offspring of patients with type 2 diabetes participating in the 
European Network on Functional Genomics of Type 2 Diabetes (EUGENE2) project33. Exclusion criteria 
included: history of type 1 and type 2 diabetes, malignant diseases, inflammatory bowel diseases and gastroin-
testinal disorders associated with malabsorption, chronic pancreatitis, use of drugs able to interfere with glu-
cose homeostasis and levels of inflammatory markers such as steroids and oral contraceptive agents, history of 
alcohol abuse, immunological or rheumatic diseases, acute and chronic infections or positivity for antibodies 
to hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg). Individuals were consecutively recruited at 
the Department of Medical and Surgical Sciences of the University ‘Magna Graecia’ of Catanzaro as previously 
described33,34. All subjects were of European ancestry and underwent anthropometrical evaluation including 
measurements of body mass index (BMI), waist circumference, and body composition assessed by bioelectrical 
impedance. A 75 g oral glucose tolerance test (OGTT) was performed with 0, 30, 60, 90 and 120 min sampling 
for plasma glucose and insulin assays. Insulin sensitivity was determined by euglycemic hyperinsulinemic clamp 
study, as previously described34. Briefly, a priming dose of insulin (Humulin, Eli Lilly & Co., Indianapolis, IN) 
was administered during the initial 10 min to acutely raise plasma insulin followed by continuous insulin infu-
sion fixed at 40 mU/m2 × min. The blood glucose level was maintained constant during the 2-h clamp study by 
infusing 20% glucose at varying rates according to blood glucose measurements assessed by a glucose analyzer at 
5 minute intervals (mean coefficient of variation of blood glucose was <5%).
The study was approved by the local ethics committee (Comitato Etico Azienda Ospedaliera “Mater Domini”). 
Written informed consent was obtained from each participant before commencing the study, in accordance with 
the principles of the Declaration of Helsinki.
Analytical determinations. Glucose, triglycerides, total and high density lipoprotein (HDL) cholesterol 
concentrations were determined by enzymatic methods (Roche, Basel, Switzerland). Serum insulin concentra-
tions were determined with a chemiluminescence-based assay (Immulite®, Siemens, Italy). White blood cell 
count was determined using an automated particle counter (Siemens Healthcare Diagnostics ADVIA® 120/2120 
Hematology System, Italy). Serum levels of high sensitivity C reactive protein (hsCRP), complement C3, total IgG, 
IgG1, IgG2, IgG3 and IgG4 subclasses were assayed by an automated nephelometric technology using the BN™II 
System analyzer with high levels of sensibility and specificity (Siemens Healthcare, Italy). Glycated hemoglo-
bin (HbA1c) was assessed by high performance liquid chromatography employing a National Glycohemoglobin 
Standardization Program certified automated analyzer (Adams HA-8160 HbA1C analyzer, Menarini, Italy).
Calculations. Glucose disposal was calculated as the mean rate of glucose infusion measured during the 
last 60 min of the clamp examination (steady-state) and it is expressed as milligrams per minute per kilogram 
fat-free mass measured with the use of electrical bioimpedance. The HOMA-IR index was calculated as fasting 
insulin × fasting glucose/22.535. The liver IR index was calculated using the formula: −0.091 + (log insulin area 
under the curve [AUC] 0–120 min × 0.400) + (log fat mass % × 0.346) − (log HDL Cholesterol × 0.408) + (log 
BMI × 0.435)15. The glucose0–30 (AUC) × insulin0–30 (AUC) index of hepatic resistance to insulin was calculated 
as reported14. The muscle insulin sensitivity index was calculated as the rate of decline in plasma glucose concen-
tration divided by mean plasma insulin concentration during OGTT as described by Abdul-Ghani MA et al.14. 
The QUICKI index was calculated using the formula: 1/(log insulin0 + log glucose0) as reported36. The Stumvoll 
ISIOGTT was calculated as 0.226 − 0.0032 × BMI − 0.0000645 × Insulin120 − 0.00375 × Glucose9037. The Matsuda 
index was calculated as 10,000/square root of [fasting glucose (mmol/L) × fasting insulin (mU/L)] × [mean 
glucose × mean insulin during OGTT]38. The Gutt’s ISI0,120 index insulin sensitivity was calculated using the 
formula: (m/[(G0 + G120)/2])/log [(I0 + I120)/2] where m = (75,000 mg + (fasting glucose − 2-h glucose) × 0.19 × 
body weight)/120 min (glucose in mg/dl; insulin in µIU/ml) as previously described39.
Statistical analysis. The results for continuous variables are given as means ± SD. Variables with skewed 
distribution including triglycerides, fasting insulin, HOMA-IR index, glucose0–30 (AUC) × insulin0–30 (AUC) 
index, Gutt’s ISI0,120, Stumvoll ISIOGTT, Matsuda, muscle insulin sensitivity index and hsCRP were natural log 
transformed for statistical analyses. Unpaired Student’s t was used to compare differences of continuous variables 
between two groups. Relationships between variables were determined by Pearson’s correlation coefficient (r). 
Partial correlation coefficients adjusted for age and gender were computed between variables. A multivariable 
linear regression analysis was performed in order to evaluate the independent contribution of IgG isotypes and 
other inflammatory and metabolic variables to insulin sensitivity. The variance inflection factor (VIF) was less 
than 2 in all the analyses indicating that multicollinearity among variables was not a problem in the multiple 
regression models. The normality of the standardized residuals was tested using the Kolmorogov-Smirnov test 
that was >0.05 indicating a normal distribution of the residuals in the multiple regression model.
All tests were two-sided, and a P value < 0.05 was considered statistically significant. All analyses were per-
formed using SPSS (Chicago, IL, USA) software programme Version 22.0 for Windows.
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Ethical approval and informed consent statement. The study was approved by the local ethics com-
mittee (Comitato Etico Azienda Ospedaliera “Mater Domini”). Written informed consent was obtained from 
each study participant. All procedures were performed in accordance with the principles of the Declaration of 
Helsinki.
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